Parallel Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Parallel Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-117	Closed	-$491	–	3594
2023 Q1	$491	Buy	117 +84	+255%	+$436	﹤0.01%	3123
2022 Q4	$198	Buy	+33	New	+$180	﹤0.01%	3193
2022 Q3	–	Sell	-29	Closed	–	–	3669
2022 Q2	$0	Buy	+29	New	+$148	﹤0.01%	3533

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Parallel Advisors's CTIC Position: Q2 2023 in Review

Parallel Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 117 shares — an estimated $491 sold.

Parallel Advisors first reported a position in CTIC in Q2 2022 and held it in 3 quarters. The position peaked at $491 in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Parallel Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Parallel Advisors sold 117 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $491.
Parallel Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 3 quarters.
Parallel Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $491 in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Parallel Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.